Abstract
Rilopirox, 6-[[p-chlorophenoxy )phenoxy]methyl]-1 hydroxy-4-methyl-2(1H)-pyridone, is a new fungicidal antimycotic with very low water solubility. It was designed to meet the demand for an Intravaginal antifungal with a long skin retention time and a strong killing effect on pathogenic yeasts. In addition, it inhibits all common fungal pathogens in the range 0.98 to 15.6 μg/ml. Fungicidal rates vis-à-vis Trichophyton mentagrophytes and Candida albicans under proliferative and non-proliferative conditions are higher than those achieved with common azole and allylamine antifungals. Rilopirox is affected by Fe3+ mos and high concentrations of human serum owing to its chelating activity. The peptone source is of utmost importance to the inhibitory activity of rilopirox whereas the pH value seems to be unimportant so long as it is within the range 5-8.5. Rilopirox appears to meet the demand for an mtravaginal antifungal as a result of its very low water solubility of 50 ng/ ml and its immediate fungicidal action even under non-proliferative conditions.